We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Bio-Rad Laboratories (BIO - Free Report) closed at $364.78 in the latest trading session, marking a -0.46% move from the prior day. This change lagged the S&P 500's 0.37% gain on the day. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq lost 1.26%.
Coming into today, shares of the maker of instruments used in biomedical research had lost 1.95% in the past month. In that same time, the Medical sector gained 0.08%, while the S&P 500 gained 4.31%.
Investors will be hoping for strength from Bio-Rad Laboratories as it approaches its next earnings release. The company is expected to report EPS of $2.90, down 14.2% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $696.05 million, up 0.72% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.12 per share and revenue of $2.91 billion. These totals would mark changes of -2.08% and +3.8%, respectively, from last year.
Any recent changes to analyst estimates for Bio-Rad Laboratories should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Bio-Rad Laboratories currently has a Zacks Rank of #4 (Sell).
Investors should also note Bio-Rad Laboratories's current valuation metrics, including its Forward P/E ratio of 25.95. Its industry sports an average Forward P/E of 24.52, so we one might conclude that Bio-Rad Laboratories is trading at a premium comparatively.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know
Bio-Rad Laboratories (BIO - Free Report) closed at $364.78 in the latest trading session, marking a -0.46% move from the prior day. This change lagged the S&P 500's 0.37% gain on the day. At the same time, the Dow lost 0.01%, and the tech-heavy Nasdaq lost 1.26%.
Coming into today, shares of the maker of instruments used in biomedical research had lost 1.95% in the past month. In that same time, the Medical sector gained 0.08%, while the S&P 500 gained 4.31%.
Investors will be hoping for strength from Bio-Rad Laboratories as it approaches its next earnings release. The company is expected to report EPS of $2.90, down 14.2% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $696.05 million, up 0.72% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.12 per share and revenue of $2.91 billion. These totals would mark changes of -2.08% and +3.8%, respectively, from last year.
Any recent changes to analyst estimates for Bio-Rad Laboratories should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Bio-Rad Laboratories currently has a Zacks Rank of #4 (Sell).
Investors should also note Bio-Rad Laboratories's current valuation metrics, including its Forward P/E ratio of 25.95. Its industry sports an average Forward P/E of 24.52, so we one might conclude that Bio-Rad Laboratories is trading at a premium comparatively.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.